Japan is considering a new approach to its “special” market expansion re-pricing that would exclude drug sales tied to private…
BUSINESS
Chugai, Japan Govt Cut Supply Deal for COVID-19 Antibody Cocktail
Chugai Pharmaceutical said on May 10 that it has agreed with the Japanese government to secure this year’s domestic supply for its COVID-19 antibody cocktail, which was originated by Regeneron Pharmaceuticals, if approved. The antibody cocktail pairing casirivimab and imdevimab,…
To read the full story
Related Article
- Japan Approves Ronapreve to Prevent Symptomatic COVID-19
November 5, 2021
- Ronapreve Clears Key Panel for COVID-19 Prevention, SC Use
November 5, 2021
- Ronapreve Up for PAFSC Review for Preventive Use on Nov. 4
October 29, 2021
- Chugai Seeks Japan Nod for Ronapreve in Prophylaxis, Asymptomatic COVID-19
October 12, 2021
- Japan Approves COVID-19 Antibody Cocktail, 1st Drug for Mild Cases
July 20, 2021
- Chugai’s Antibody Cocktail Up for PAFSC Review on July 19, 4th COVID-19 Drug If Approved
July 13, 2021
- Chugai Files Regeneron’s Antibody Cocktail in Japan
June 30, 2021
- Chugai Presses on with Japan Development of 3 COVID-19 Drugs, Aims for Antibody Cocktail Filing in 2021: President
May 14, 2021
- Chugai Eyes Japan Submission for COVID-19 Antibody Cocktail by Year-End
April 23, 2021
- Chugai to Develop Regeneron’s COVID-19 Antibody Cocktail in Japan
December 11, 2020
- Chugai, Roche Discussing Japan Development of Regeneron's COVID-19 Antibody Cocktail
October 16, 2020
BUSINESS
- AG Price Parity Plan Stokes Industry Fears of Patient, Pharmacy Defections
December 12, 2025
- Kyowa Kirin Names Abdul Mullick as Next CEO from March 2026
December 12, 2025
- Regeneron Files Libtayo for Squamous Cell Carcinoma in Japan
December 12, 2025
- Chugai to Donate 100 Million Yen to Support Nobel Laureate Sakaguchi’s Research
December 12, 2025
- Regeneron Lines Up 5 Late-Stage Assets for Japan: Commercial Head
December 11, 2025
Japan has presented its latest draft policy direction for its FY2026 drug pricing reform. While the package includes a string…
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…